IrinoSym 100 Injection contains Irinotecan at a concentration of 20 mg/ml and is indicated for the treatment of metastatic colorectal cancer and other malignancies as determined by clinical evaluation. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells. The injection is administered intravenously under the supervision of an oncology specialist, with dosage and schedule tailored to the patient’s clinical condition, prior treatment history, and tolerance. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, and fatigue, necessitating careful monitoring of hematologic parameters and supportive care measures. Hypersensitivity reactions may occur, and premedication with antiemetics and atropine is recommended to mitigate cholinergic symptoms. IrinoSym 100 Injection should be used with caution in patients with hepatic impairment or pre-existing gastrointestinal disorders. It is contraindicated in patients with known hypersensitivity to irinotecan or any component of the formulation. Due to its cytotoxic nature, appropriate handling and disposal procedures must be followed to prevent exposure to healthcare personnel. IrinoSym 100 Injection is a critical component in combination chemotherapy regimens aimed at improving survival and quality of life in patients with advanced malignancies.